It's looking like the next few years will be tough for the pharmas, with top-selling drugs going off-patent, and generics cutting $67 billion from annual sales between 2007 and 2012. Meanwhile, with fewer drugs coming available, new sources of revenue are comparatively scarce. To address these looming threats, expect to see the industry transform itself in coming years, observers say. FiercePharma